表紙
市場調查報告書

Exportin1:開發中產品分析

Exportin 1 - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 372678
出版日期 內容資訊 英文 111 Pages
訂單完成後即時交付
價格
Back to Top
Exportin1:開發中產品分析 Exportin 1 - Pipeline Review, H2 2019
出版日期: 2019年12月27日內容資訊: 英文 111 Pages
簡介

本報告提供以Exportin1為標的之治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

Exportin1 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Karyopharm Therapeutics, Inc.
  • Stemline Therapeutics, Inc.

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC2158TDB

Summary

According to the recently published report 'Exportin 1 - Pipeline Review, H2 2019'; Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) pipeline Target constitutes close to 7 molecules.

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Exportin 1 (XPO1) or chromosomal maintenance 1 (CRM1) is a eukaryotic protein. It mediates the nuclear export of cellular proteins bearing a leucine-rich nuclear export signal (NES) and of RNAs. In association with RANBP3, it binds cooperatively to the NES on its target protein and to the GTPase RAN in its active Ran-GTP. Docking of this complex to the nuclear pore complex (NPC) is mediated through binding to nucleoporins. It is involved in U3 snoRNA transport from Cajal bodies to nucleoli.

The report 'Exportin 1 - Pipeline Review, H2 2019' outlays comprehensive information on the Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase II, Phase I and Preclinical stages are 1, 1, 3 and 2 respectively. Report covers products from therapy areas Oncology, Immunology, Central Nervous System, Genetic Disorders and Infectious Disease which include indications Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Diffuse Large B-Cell Lymphoma, Prostate Cancer, Colorectal Cancer, Gastrointestinal Tumor, Glioblastoma Multiforme (GBM), Malignant Mesothelioma, Metastatic Colorectal Cancer, Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Myelofibrosis, Non-Small Cell Lung Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Systemic Lupus Erythematosus, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenocarcinoma, Amyotrophic Lateral Sclerosis, Anaplastic Large Cell Lymphoma (ALCL), Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Bone Sarcoma, Breast Cancer, Burkitt Lymphoma, Cervical Cancer, Chondrosarcoma, Dedifferentiated Liposarcoma, Duchenne Muscular Dystrophy, Endometrial Cancer, Epstein-Barr Virus (HHV-4) Infections, Ewing Sarcoma, Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma), Fallopian Tube Cancer, Follicular Lymphoma, Gastroesophageal (GE) Junction Carcinomas, Gastrointestinal Stromal Tumor (GIST), High-Grade Glioma, Human Immunodeficiency Virus (HIV) Infections (AIDS), Leiomyosarcoma, Liposarcoma, Mantle Cell Lymphoma, Melanoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Multiple Sclerosis, Natural Killer Cell Lymphomas, Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET), Neuroendocrine Tumors, Non-Hodgkin Lymphoma, Ovarian Cancer, Peripheral T-Cell Lymphomas (PTCL), Peritoneal Cancer, Post-Polycythemia Vera Myelofibrosis (PPV-MF), Post-Transplant Lymphoproliferative Disorder, Primary Mediastinal B-Cell Lymphoma, Recurrent Glioblastoma Multiforme (GBM), Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Acute Myeloid Leukemia, Relapsed Chronic Lymphocytic Leukemia (CLL), Respiratory Syncytial Virus (RSV) Infections, Rheumatoid Arthritis, Small-Cell Lung Cancer, Soft Tissue Sarcoma, Solid Tumor, Synovial Sarcoma, Thymoma (Thymic Epithelial Tumor), Traumatic Brain Injury, Triple-Negative Breast Cancer (TNBC), Unspecified Influenza Virus Infections, Urinary Tract Cancer and Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).

Scope

  • The report provides a snapshot of the global therapeutic landscape for Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1)
  • The report reviews Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Overview
  • Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Companies Involved in Therapeutics Development
  • Biogen Inc
  • CanBas Co Ltd
  • Karyopharm Therapeutics Inc
  • Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Drug Profiles
  • BIIB-100 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • eltanexor - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • felezonexor - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • KPT-251 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • KPT-276 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • selinexor - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • verdinexor - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Dormant Products
  • Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Discontinued Products
  • Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Product Development Milestones
  • Featured News & Press Releases
  • Dec 08, 2019: Karyopharm presents Eltanexor (KPT-8602) data at the American Society of Hematology 2019 Annual Meeting
  • Dec 08, 2019: Karyopharm presents XPOVIO (Selinexor) data at the American Society of Hematology 2019 Annual Meeting
  • Dec 07, 2019: Karyopharm reports new and updated XPOVIO (Selinexor) data in relapsed or refractory multiple myeloma at the American Society of Hematology 2019 Annual Meeting
  • Nov 06, 2019: Karyopharm presents an abstract on eltanexor at the American Society of Hematology 2019 Annual Meeting
  • Nov 06, 2019: Karyopharm announces XPOVIO (Selinexor) clinical data to be presented at the American Society of Hematology 2019 Annual Meeting
  • Oct 30, 2019: UAB research identifies drug to help Duchenne muscular dystrophy symptoms
  • Oct 08, 2019: XPOVIO (selinexor) now available to Excelera network members for treatment of Relapsed or Refectory Multiple Myeloma
  • Oct 01, 2019: Stemline Therapeutics recaps Felezonexor (SL-801) clinical data presentation from ESMO 2019 Congress
  • Oct 01, 2019: AmerisourceBergen selected by Karyopharm to support XPOVIO
  • Sep 27, 2019: Stemline Therapeutics announces Felezonexor (SL-801) clinical data to be featured at upcoming ESMO 2019 congress
  • Sep 13, 2019: Karyopharm announces XPOVIO (Selinexor) presentations at the 17th International Myeloma Workshop
  • Aug 21, 2019: Unprecedented therapy found effective for blood cancer patients with no treatment options
  • Aug 21, 2019: Karyopharm announces publication of XPOVIO (Selinexor) phase 2b STORM study results in The New England Journal of Medicine
  • Jul 24, 2019: Moffitt research of Selinexor for relapsed/refractory multiple myeloma facilitates recent FDA approval
  • Jul 17, 2019: A new cancer drug, thanks to a new approach
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indications, H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..3), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..3), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..4), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..5), H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Biogen Inc, H2 2019
  • Pipeline by CanBas Co Ltd, H2 2019
  • Pipeline by Karyopharm Therapeutics Inc, H2 2019
  • Dormant Products, H2 2019
  • Dormant Products, H2 2019 (Contd..1), H2 2019
  • Dormant Products, H2 2019 (Contd..2), H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
Back to Top